Yahoo · Sep 15, 2026
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re
NASDAQ · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$161.85
Down-$1.93 (-1.18%)
Updated Sep 16, 2026, 6:59 AM
SID Score
7.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 279.95B
- P/E ratio
- 33.06
- Dividend yield
- 0.95%
- 52-week range
- $72.90 – $212.71
- Volume
- 2.94M
- Avg. volume
- 5.47M
Price performance
AZN price history
1M range · 20 trading sessions · Daily adjusted prices
AZN closed at $161.85 after 20 trading sessions, up 1.09% for the selected period.
- Last close
- $161.85
- Period change
- +1.09%
- Period low
- $156.94
- Period high
- $169.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $161.42 | $163.90 | $160.71 | $161.85 | 2.94M |
| Sep 14, 2026 | $164.08 | $164.55 | $162.14 | $163.78 | 3.09M |
| Sep 11, 2026 | $161.43 | $161.51 | $158.13 | $160.17 | 2.23M |
| Sep 10, 2026 | $157.68 | $160.30 | $157.23 | $159.64 | 2.94M |
| Sep 9, 2026 | $158.31 | $159.1301 | $156.74 | $156.94 | 3.87M |
| Sep 8, 2026 | $163.96 | $163.96 | $159.40 | $160.04 | 5.15M |
| Sep 4, 2026 | $162.82 | $163.78 | $161.13 | $162.70 | 3.07M |
| Sep 3, 2026 | $165.64 | $165.74 | $162.24 | $164.77 | 2.43M |
| Sep 2, 2026 | $162.54 | $164.69 | $160.87 | $161.63 | 3.3M |
| Sep 1, 2026 | $163.66 | $164.24 | $161.385 | $162.47 | 2.6M |
| Aug 31, 2026 | $162.70 | $163.75 | $161.95 | $162.13 | 3.07M |
| Aug 28, 2026 | $163.52 | $163.54 | $161.18 | $162.70 | 2.88M |
| Aug 27, 2026 | $165.27 | $165.58 | $163.98 | $164.52 | 2.5M |
| Aug 26, 2026 | $167.46 | $167.89 | $165.17 | $166.27 | 2.68M |
| Aug 25, 2026 | $167.08 | $170.18 | $166.78 | $169.66 | 3.45M |
| Aug 24, 2026 | $164.57 | $167.08 | $163.97 | $166.71 | 2.78M |
| Aug 21, 2026 | $164.04 | $167.25 | $163.96 | $165.98 | 3.18M |
| Aug 20, 2026 | $163.40 | $165.57 | $161.475 | $164.49 | 5.09M |
| Aug 19, 2026 | $162.13 | $165.91 | $162.00 | $164.95 | 3.82M |
| Aug 18, 2026 | $159.12 | $160.64 | $158.98 | $160.10 | 3M |
Latest AZN news
The latest Smart Investors Daily articles mentioning AZN.
Stock researchCompany · Overview
AZN research
Overview
Company profile and research snapshot.
Company profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.67
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
News briefing
Generated Sep 15, 2026, 9:03 PM
Why Is AZN Down Today?
AstraZeneca shares declined 1.18% today as mixed signals from the company's oncology pipeline weighed on investor sentiment. While the healthcare sector posted premarket gains, AZN's recent clinical trial setbacks appear to be offsetting any broader market tailwinds for the pharmaceutical giant.
Bottom line: AstraZeneca's 1.18% decline reflects justified market concern over the Etcamah breast cancer study failure, which significantly narrows the commercial opportunity for a recently approved asset in a competitive oncology market. While two other pipeline wins provide some offsetting positive news, investors should monitor upcoming oncology trial results closely as the key catalyst for recovery, particularly given the sector's execution-dependent nature and AZN's reliance on pipeline success for growth.
Yahoo · Sep 15, 2026
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology growth opportunities. The trial evaluated Etcamah plus Pfizer’s Ibrance (palbociclib) in previously untreated patients with ER-positive, HER2-negative advanced breast cancer and found a numerical improvement […]
Yahoo · Sep 15, 2026
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
Yahoo · Sep 15, 2026
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Execut
AI research layers
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC Stock Performance
AstraZeneca PLC shares trade at $163.78, reflecting a modest 1.05% gain over the past month but a notable 12.13% decline over the trailing three-month period, per SID market data. Despite this recent pullback, the stock has delivered a strong 97.21% return over the past twelve months, underscoring significant long-term appreciation. Technically, AZN currently trades below its 50-day moving average of $166.78 but above its 200-day moving average of $161.76, suggesting the stock sits in a near-term consolidation zone between key support and resistance levels. The 14-day relative strength index stands at 39.1, approaching oversold territory and indicating weakened short-term momentum. AstraZeneca maintains a low beta of 0.168, according to Massive/Polygon data, reflecting substantially lower volatility than the broader market. Average daily trading volume registers at approximately 5.47 million shares, supporting adequate liquidity for institutional participants.
AstraZeneca PLC Valuation Analysis
AstraZeneca carries a market capitalization of approximately $279.9 billion, positioning it among the largest global pharmaceutical companies, per SID market data. The stock trades at a price-to-earnings ratio of 33.06, which represents a premium relative to the broader Healthcare sector, while the PEG ratio of 4.53 suggests the current valuation may be elevated when adjusted for expected earnings growth. According to SEC filings, AstraZeneca's price-to-book ratio stands at 6.24, reflecting the market's recognition of substantial intangible assets including its oncology and rare disease pipeline. The company offers a dividend yield of 1.56%, providing a modest income component for shareholders. The premium valuation metrics collectively indicate that investors are pricing in continued pipeline execution and revenue growth from key therapeutic franchises. The elevated PEG ratio warrants monitoring relative to forward earnings delivery and margin trajectory in upcoming quarters.
Smart Money Activity for AZN
AstraZeneca's composite smart money score stands at 58 out of 100 with a neutral overall signal, per SID market data. The institutional component registers a perfect 25 out of 25, indicating maximum conviction from large fund managers and sustained accumulation patterns in recent filings. According to SEC Form 4 filings, insider activity has been modestly positive, with 2 insider purchases and zero sales recorded over the past 90 days, contributing to an insider sub-score of 12.5 out of 25. Congressional trading activity scores 12 out of 25, reflecting moderate but not outsized interest from legislators with disclosed positions. The dark pool sub-score of 8.9 out of 25 represents the weakest component, suggesting limited off-exchange block transaction activity relative to historical norms. The divergence between strong institutional ownership signals and subdued dark pool activity creates a mixed picture, though the absence of insider selling and presence of insider buying provide a constructive undercurrent for the stock according to 13F institutional filings.
AstraZeneca PLC Earnings Outlook
AstraZeneca has demonstrated consistent earnings outperformance in its most recently reported quarters, according to company earnings reports. In the quarter reported July 27, 2026, AZN posted actual earnings of $2.63 per share against a consensus estimate of $1.52, representing a positive surprise of $1.11 or approximately 73%. The prior quarter similarly exceeded expectations, delivering $2.58 per share versus the $1.53 estimate, a $1.05 beat of roughly 69%. These substantial upside surprises reflect strong execution across AstraZeneca's oncology, cardiovascular, and rare disease portfolios. Looking ahead, analyst estimates project earnings of $1.75 per share for the upcoming April 28 report and $1.44 per share for the July 28 report. The forward estimates appear conservative given the magnitude of recent beats, though seasonal and pipeline-related variability could influence results. Investors will monitor whether the pattern of significant earnings outperformance continues in forthcoming quarters.
Wall Street Analyst Ratings for AZN
Wall Street analyst sentiment on AstraZeneca remains divided, per SID consensus data. The most recent rating came from Berenberg Bank on July 13, 2026, reiterating a Buy recommendation on AZN shares. Jefferies has also maintained a bullish stance, issuing Buy reiterations on both June 26 and June 9, 2026, reflecting confidence in AstraZeneca's pipeline and commercial trajectory. Conversely, Deutsche Bank represents the bearish counterpoint, reiterating a Sell rating on June 26 and June 11, 2026, marking it as the most prominent negative voice among recent coverage updates. This creates a notable bifurcation in analyst views, with two firms firmly in the Buy camp and one maintaining a Sell. According to Wall Street analyst reports, the disagreement likely centers on valuation sustainability given the stock's 33.06 P/E multiple versus forward growth expectations. The concentration of activity in June and July 2026 suggests heightened analyst attention, potentially driven by pipeline catalysts and competitive dynamics within the pharmaceutical landscape.
